Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma (Q39846045)

15 September 2017

Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma (English)

1 reference

15 September 2017

0 references

1 reference

Jacqueline Morgan

1

1 reference

15 September 2017

Anna V Hoekstra

2

1 reference

15 September 2017

Eloise Chapman-Davis

3

1 reference

15 September 2017

Jennifer L Hardt

4

1 reference

15 September 2017

J Julie Kim

5

1 reference

15 September 2017

Barbara M Buttin

6

1 reference

15 September 2017

language of work or name

English

0 references

publication date

24 May 2009

1 reference

15 September 2017

1 reference

15 September 2017

114

1 reference

15 September 2017

293-298

1 reference

15 September 2017

2

1 reference

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

15 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Uterine papillary serous carcinoma: patterns of metastatic spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Endometrial papillary serous carcinoma: patterns of spread and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Treatment of uterine papillary serous carcinoma with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Blockade of AP1 transactivation abrogates the abnormal expression of breast cancer-specific gene 1 in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Overexpression of synuclein-gamma in pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

p53-independent apoptosis induced by paclitaxel through an indirect mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.04.036

10.1016/J.YGYNO.2009.04.036

7 January 2021

Identifiers

DOI

1 reference

15 September 2017

1 reference